In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.
There were 18 new drug licensing deals in August 2021, the most in eight months. The 12 deals that were publicly disclosed reached a total value of $3.44 billion, representing another record.
China’s biotech industry saw a dip in deal volume and value for innovative drugs in July after a rebound in the previous month. Chinese biotech companies made a total of 10 deals, with disclosed deal value amounting to over $1.5 billion.
LianBio Acquires Three Potential FIC Therapies for Cancer and IBD.
CANbridge Secures Two In-Licensing Deals for Rare Disease Therapies.